These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12497860)

  • 1. [Clinical trials. When and why: the principle of randomization and double-blind method].
    de Giuli F
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):973-5. PubMed ID: 12497860
    [No Abstract]   [Full Text] [Related]  

  • 2. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
    Haahr MT; Hróbjartsson A
    Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing allocation concealment and blinding in randomized controlled trials: why bother?
    Schulz KF
    ACP J Club; 2000; 132(2):A11-2. PubMed ID: 10750446
    [No Abstract]   [Full Text] [Related]  

  • 4. [Continuing education. Clinical trials].
    Sökeland J
    Urologe A; 1990 Nov; 29(6):W41-2. PubMed ID: 2291253
    [No Abstract]   [Full Text] [Related]  

  • 5. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations].
    Dorhout Mees EJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2228. PubMed ID: 11103264
    [No Abstract]   [Full Text] [Related]  

  • 6. Blinding in clinical trials, time to do it better.
    Park J; Bang H; Cañette I
    Complement Ther Med; 2008 Jun; 16(3):121-3. PubMed ID: 18534323
    [No Abstract]   [Full Text] [Related]  

  • 7. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 8. Masked monitoring in clinical trials--blind stupidity?
    Meinert CL
    N Engl J Med; 1998 May; 338(19):1381-2. PubMed ID: 9571262
    [No Abstract]   [Full Text] [Related]  

  • 9. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods.
    Devereaux PJ; Choi PT; El-Dika S; Bhandari M; Montori VM; Schünemann HJ; Garg AX; Busse JW; Heels-Ansdell D; Ghali WA; Manns BJ; Guyatt GH
    J Clin Epidemiol; 2004 Dec; 57(12):1232-6. PubMed ID: 15617948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Randomization, informed consent and double-blind].
    Navarro FA; López-Gil JA
    Med Clin (Barc); 1992 Jan; 98(2):78. PubMed ID: 1545635
    [No Abstract]   [Full Text] [Related]  

  • 11. Regarding "omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study".
    Gilbert DL
    Biol Psychiatry; 2008 Jan; 63(2):e13; author reply e15. PubMed ID: 17555722
    [No Abstract]   [Full Text] [Related]  

  • 12. What we can learn from open-label extensions of randomized clinical trials.
    Cummings JL
    Arch Neurol; 2006 Jan; 63(1):18-9. PubMed ID: 16401732
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylactic ilioinguinal neurectomy in open inguinal hernia repair: a double-blind randomized controlled trial.
    Lange JF; Wijsmuller A; van Geldere D
    Ann Surg; 2007 Dec; 246(6):1116. PubMed ID: 18043120
    [No Abstract]   [Full Text] [Related]  

  • 14. Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge.
    Chinchilli VM; Fisher L; Craig TJ
    J Allergy Clin Immunol; 2005 Mar; 115(3):592-7. PubMed ID: 15753909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double blind, you are the weakest link--good-bye!
    Devereaux PJ; Bhandari M; Montori VM; Manns BJ; Ghali WA; Guyatt GH
    ACP J Club; 2002; 136(1):A11. PubMed ID: 11829579
    [No Abstract]   [Full Text] [Related]  

  • 16. The quality of reporting and outcome measures in randomized clinical trials related to upper-extremity disorders.
    Gummesson C; Atroshi I; Ekdahl C
    J Hand Surg Am; 2004 Jul; 29(4):727-34; discussion 735-7. PubMed ID: 15249101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure.
    O'Connor CM; Gattis WA; Teerlink JR; Adams KF; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S47-50. PubMed ID: 12594451
    [No Abstract]   [Full Text] [Related]  

  • 18. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 20. [Contemporary opinion on placebo].
    Bogdanik T
    Przegl Lek; 1996; 53(6):481-5. PubMed ID: 8927750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.